Novo Nordisk A/S
Copenhagen : NOVO B

March 18, 2013 07:41 ET

Novo Nordisk A/S: People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial

BAGSVAERD, DENMARK--(Marketwire - Mar 18, 2013) -

Company announcement No 19 / 2013:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Contact Information